Cantor Fitzgerald给予Metsera"增持"评级 看好其肥胖药物市场前景
Cantor Fitzgerald的分析指出，未来一年可能出现多个有利于Metsera估值的催化剂。分析师表示，当前估值可能反映约100%的上涨空间，强调了公司股票的强劲增长前景。分析师设定的目标价为56美元，暗示有显著的上涨潜力。欲了解更多关键指标和见解，请查看 InvestingPro ，其提供MTSR的额外独家提示。
腾讯网13 小时
DataEye海外短剧热榜：欧美流行“一胎6宝”？这一市场男频崛起
文 | DataEye一、DataEye海外短剧热榜总榜本期（2月17日-2月23日）DataEye海外短剧热榜总榜中，《Mafia's Tender Torture》登顶；《Love Again, My Princess》第二；《Carrying ...
經濟通ET Net14 小时
{Block Trade}BABA-W (09988): 387k shares, or HK$50.45m
[ET Net News Agency, 25 February 2025] A direct manual trade of 387,000 shares of BABA-W (09988) was registered at 2:53p.m. The deal amounted to HK$50.45m, or at HK$130.35 per share, 3.9% lower than p ...
腾讯网16 小时
Shanghai Then and Now: 世博文化公园
Shanghai Expo Culture Park 世博文化公园Pudong District /浦东新区Shanghai Expo Culture Park, once the No. 3 Shanghai Steel Factory and a ...
經濟通ET Net18 小时
{Block Trade}HKEX (00388): 183k shares, or HK$62.45m
The deal amounted to HK$62.45m, or at HK$340.9 per share, 1.4% lower than previous close. HKEX is now trading down 1.22% to HK$341.4, with 4.55 million shares of HK$1.54b ...